ArticleFrontiers in cellular and infection microbiology2020
Treatment and Outcomes of Infections Caused by Diverse Carbapenemase-Producing Carbapenem-Resistant
Article in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluation of three variants of the carbapenem inactivation method for carbapenemase detection inJAC-antimicrobial resistance · 2026Article
- Early procalcitonin kinetics as an independent predictor of mortality in multi-drug resistant Klebsiella spp. bloodstream infections: a retrospective cohort study.BMC infectious diseases · 2026Observational
- Observational
- Understanding the landscape of carbapenemase-producing organisms (CPOs), and spotlighting opportunities for control in England.Infection prevention in practice · 2025Review
- Identification of biomarkers for knee osteoarthritis through clinical data and machine learning models.Scientific reports · 2025Article
- Gastrointestinal carriage of carbapenemase-producing enterobacterales among inpatient and outpatient children in Kenya.Scientific reports · 2024Article
- Raman spectrum combined with deep learning for precise recognition of Carbapenem-resistant Enterobacteriaceae.Analytical and bioanalytical chemistry · 2024Article
- Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model.Antibiotics (Basel, Switzerland) · 2023Article
- Genomic and proteomic characterization of two strains of Shigella flexneri 2 isolated from infants' stool samples in Argentina.BMC genomics · 2022Article
- Association Between Types of Carbapenemase and Clinical Outcomes of Infection Due to Carbapenem Resistance Enterobacterales.Infection and drug resistance · 2022Article
- Risk Factors and Clinical Impact of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Estimating the economic cost of carbapenem resistant Enterobacterales healthcare associated infections in Singapore acute-care hospitals.PLOS global public health · 2022Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection.Drug target insightsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.